Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 8/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548956 | 0.87 | HPGD (0.48) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL8217780 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL16984146 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL1709273 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL28499349 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL27144761 | 0.84 | HPGD (0.49) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL734925 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL9942499 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL733741 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2GPR119HPGD | |
| SCHEMBL19785380 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2GPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | USP2 4800/4885SMN1; SMN2 4301/4885EPHX2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.